Zepbound beats Wegovy for weight loss
Digest more
In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices. President Donald Trump's executive order demands that drugmakers cut prices on their products in the coming months to hew more closely to what they charge in other developed countries,
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
NEW YORK (Reuters) -Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly increased use of the new blockbuster medicines.